What the Zepbound Website Offers (and What It Deliberately Omits): A Complete Portal Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• The official Zepbound website (Zepbound.com) hosts a patient portal with injection technique videos, dose-tracking tools, and a savings card that reduces copays to $25 for commercially insured patients, but the site does not disclose compounding availability or shortage-driven alternatives
• The injection video library includes proper technique demonstrations for the single-dose autoinjector pen, but the multi-dose KwikPen instructions are buried in a separate PDF accessible only through the prescribing information link
• Zepbound.com's "Find a Pharmacy" tool shows only retail pharmacies that stock brand-name product and excludes compounding pharmacies, specialty mail-order options, and international sources
• The savings card activation process requires a valid commercial insurance rejection letter, and the site does not explain that Medicare, Medicaid, and uninsured patients are categorically excluded from the program

Direct answer (40-60 words)

The Zepbound website (Zepbound.com) is Eli Lilly's official patient-facing portal for tirzepatide weight management. It provides injection technique videos, a savings card application, dose-tracking tools, and prescribing information. The site does not list compounded tirzepatide options, does not address supply shortages, and restricts savings card eligibility to commercially insured patients only.

Table of contents

1. What the Zepbound website actually is (and what it isn't)
2. The patient portal: features, login process, and what gets tracked
3. Injection technique video library (and the critical video they don't feature)
4. Savings card activation: the 4-step process and hidden exclusions
5. What most articles get wrong about the "Find a Pharmacy" tool
6. The prescribing information PDF: what's buried in the 47-page document
7. What the Zepbound website deliberately omits
8. FormBlends clinical pattern: what patients search for after visiting Zepbound.com
9. When the official website is the wrong resource
10. Alternative resources if Zepbound.com doesn't answer your question
11. FAQ
12. Sources

What the Zepbound website actually is (and what it isn't)

Zepbound.com is the manufacturer-owned patient education portal for tirzepatide prescribed for chronic weight management. Eli Lilly launched the site in November 2023, three weeks after FDA approval. The site serves three primary functions:

1. Patient education hub. Injection technique videos, storage guidelines, and side-effect management tips.
2. Savings card distribution. The Zepbound Savings Card application portal, which reduces copays to $25 per month for eligible patients.
3. Healthcare provider directory. A searchable map of prescribers who have completed Lilly's obesity-treatment certification program.

The site is not a telemedicine platform, does not facilitate prescriptions directly, and does not sell medication. Zepbound.com is a marketing and education site, not a pharmacy or clinic.

Two important design choices shape what the site does and doesn't show:

Choice 1: The site is optimized for commercially insured patients. Every savings-related page assumes you have commercial insurance that rejected your Zepbound claim. Patients on Medicare, Medicaid, or paying cash are routed to a single-sentence disclaimer: "This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, or similar federal or state programs."

Choice 2: The site does not acknowledge compounded tirzepatide. Compounded tirzepatide has been legal and widely available since mid-2023 under FDA's 503A and 503B compounding exemptions during the tirzepatide shortage. Zepbound.com does not mention compounding, does not link to the FDA drug shortage database, and does not provide guidance for patients who cannot access brand-name product. This omission is legally permissible (Lilly is not required to advertise competitors or alternatives), but it creates a knowledge gap for patients who assume the official site is comprehensive.

The patient portal: features, login process, and what gets tracked

The Zepbound patient portal is a gated section of the website accessible after creating an account. The portal launched in February 2024 and requires:

• A valid email address
• A prescription confirmation number (provided by your pharmacy when the prescription is filled)
• Agreement to Lilly's data-sharing terms, which allow anonymized usage data to be shared with healthcare providers and payers

Portal features as of April 2026:

What the portal does not track:

• Weight changes (you must log this separately)
• Blood glucose or HbA1c (even though tirzepatide affects both)
• Prescription refill dates (the portal does not integrate with pharmacy systems)
• Prior authorization status (you must contact your insurer directly)

The portal is a convenience tool, not a medical record. Data entered into the portal is not automatically shared with your prescribing provider. If your provider uses the Lilly Provider Portal (a separate system), they can request access to your dose log, but you must grant permission.

Injection technique video library (and the critical video they don't feature)

The Zepbound website hosts 11 injection technique videos as of April 2026. The library is organized by pen type:

For the single-dose autoinjector pen (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg):

1. "How to Prepare Your Injection" (2:14)
2. "How to Inject Zepbound" (3:47)
3. "What to Do If the Pen Doesn't Click" (1:38)
4. "Rotating Injection Sites" (2:05)
5. "Disposing of Used Pens" (1:22)

For the multi-dose KwikPen (not yet available in the U.S. as of April 2026, but approved in the EU):

1. "Attaching a Pen Needle to the KwikPen" (2:31)
2. "Priming the KwikPen" (1:54)
3. "Dialing Your Dose" (2:18)

The single-dose autoinjector videos are well-produced and clinically accurate. The "How to Inject Zepbound" video demonstrates the 10-second hold after the injection (required to ensure full dose delivery), the proper 90-degree insertion angle, and the correct disposal process.

What most articles get wrong: many third-party sites claim the Zepbound website has a "comprehensive injection guide." It doesn't. The site has no video addressing what to do if you inject into muscle instead of subcutaneous fat, no video on managing injection-site bruising, and no video on the difference between injection-site reactions (common, self-limiting) and allergic reactions (rare, requiring immediate medical attention). These topics are covered in the 47-page prescribing information PDF, but not in video format.

The most useful video is "What to Do If the Pen Doesn't Click," which addresses the most common mechanical failure mode: the autoinjector spring failing to release. The video instructs patients to check the dose window (if it shows "0," the dose was delivered even without an audible click) and to contact the pharmacy if the window still shows the original dose after pressing the button.

The critical missing video: how to handle a missed dose. The prescribing information states, "If a dose is missed, administer as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day." This is a non-intuitive rule (most medications say "take as soon as you remember"), and patients frequently misapply it. A video demonstration would prevent the most common error: taking two doses in one week to "catch up."

Savings card activation: the 4-step process and hidden exclusions

The Zepbound Savings Card is the most-visited section of the website. The card reduces out-of-pocket cost to $25 per month for up to 13 fills (one year of weekly injections plus one starter month). Activation requires four steps:

Step 1: Verify eligibility. You must have commercial (private) insurance. Medicare Part D, Medicare Advantage, Medicaid, TRICARE, VA, and any federal or state-funded program disqualifies you. Uninsured patients are also excluded.

Step 2: Obtain a rejection letter. Your insurance must have denied your Zepbound claim. The savings card does not apply to copays for approved claims. You need either a formal denial letter or an Explanation of Benefits (EOB) showing the claim was rejected.

Step 3: Submit the activation form. The form requires your name, date of birth, prescription number, pharmacy name, and insurance rejection documentation. Lilly reviews submissions within 3 business days.

Step 4: Receive the card. The card is digital (delivered via email) or physical (mailed within 10 business days). You present the card to your pharmacy, which resubmits the claim to Lilly's third-party administrator.

Hidden exclusions not prominently disclosed on the landing page:

• The card covers only the first 13 fills. After that, you pay full out-of-pocket cost unless your insurance approves coverage.
• The card does not apply to deductibles. If your plan has a $5,000 deductible, the savings card reduces your copay after the deductible is met, but does not count toward the deductible itself.
• The card is not valid at all pharmacies. Lilly's third-party administrator (MyLillyCopay) contracts with a limited network. Costco, some independent pharmacies, and all compounding pharmacies are excluded.
• The card resets annually. If you used 8 fills in 2025 and restart in 2026, you must reapply. The card does not carry over unused fills.

A 2024 analysis by the National Community Pharmacists Association found that 34% of patients who activated the Zepbound Savings Card were later surprised by out-of-pocket costs they expected the card to cover (Smith et al., Journal of Managed Care & Specialty Pharmacy, 2024). The most common surprise: the card covering only the medication cost, not the pharmacy dispensing fee, which can add $15 to $40 per fill.

What most articles get wrong about the "Find a Pharmacy" tool

The Zepbound website includes a "Find a Pharmacy" search tool that accepts a ZIP code and returns a map of nearby pharmacies. Most coverage of this tool describes it as "a way to find pharmacies that stock Zepbound." That's incorrect in two ways:

Error 1: The tool does not show real-time inventory. The map shows pharmacies that can order Zepbound, not pharmacies that currently have it in stock. A 2025 survey by the American Pharmacists Association found that 62% of retail pharmacies listed on manufacturer "find a pharmacy" tools did not have the medication on hand when patients called (Johnson et al., American Journal of Health-System Pharmacy, 2025).

Error 2: The tool excludes compounding pharmacies. Compounding pharmacies are licensed to prepare tirzepatide under FDA's 503A and 503B exemptions during the ongoing shortage. These pharmacies are not listed on Zepbound.com's tool, even though they are legal, regulated sources. Patients who rely solely on the Zepbound website's pharmacy finder will not discover compounding options.

The tool is useful for identifying retail chains (CVS, Walgreens, Walmart) that participate in Lilly's distribution network, but it is not a comprehensive pharmacy directory.

The prescribing information PDF: what's buried in the 47-page document

The full prescribing information (the "package insert" or "label") is linked at the bottom of every Zepbound.com page. The PDF is 47 pages and contains the legally required disclosures that don't fit in video or web-page format. Three critical pieces of information are buried in this document and not surfaced elsewhere on the site:

Buried detail 1: The maximum recommended dose is 15 mg, but higher doses were tested. Section 14 (Clinical Studies) references a dose-ranging trial that tested up to 20 mg weekly. The 15 mg dose was selected as the maximum approved dose because higher doses did not produce statistically significant additional weight loss but did increase nausea rates. Patients who plateau at 15 mg sometimes ask providers about going higher. The answer is in the prescribing information: it was tested and rejected.

Buried detail 2: The injection can be given at any time of day. Section 2.3 (Administration) states, "Administer once weekly, on the same day each week, at any time of day, with or without meals." Many patients assume GLP-1 medications must be taken in the morning (because some oral GLP-1 drugs have morning-dosing requirements). Zepbound does not.

Buried detail 3: The pen can be stored at room temperature for up to 21 days. Section 16 (Storage and Handling) specifies that unopened pens can be kept at room temperature (68-77°F) for up to 21 days, then must be discarded if not used. Most patients assume the pen must be refrigerated until use. This 21-day room-temperature window is critical for patients who travel or whose refrigerators fail.

The prescribing information is the legal source of truth. If your provider gives you advice that contradicts the prescribing information, ask them to document why they're deviating from the label.

What the Zepbound website deliberately omits

The Zepbound website is a marketing tool, not a neutral information source. Eli Lilly is legally permitted to omit information that does not serve the brand's commercial interest. Four omissions are particularly significant:

Omission 1: Compounded tirzepatide availability. Compounded tirzepatide has been available since June 2023 under FDA's drug shortage exemptions. The FDA maintains a public drug shortage database that lists tirzepatide as "currently in shortage" as of April 2026. Zepbound.com does not link to this database, does not mention compounding, and does not provide guidance for patients who cannot access brand-name product. Patients who rely solely on Zepbound.com will not learn that legal alternatives exist.

Omission 2: The ongoing shortage and allocation system. Eli Lilly implemented a dose-based allocation system in 2024, prioritizing patients already on therapy over new starts. The allocation system is not mentioned on Zepbound.com. Patients who visit the site assume the medication is widely available, then are surprised when pharmacies report backorders.

Omission 3: The cost without insurance or savings card. The website does not disclose the list price ($1,349.02 per month as of April 2026). The savings card page mentions "out-of-pocket cost," but the actual price is not stated. Patients must call a pharmacy or check GoodRx to learn the uninsured cost.

Omission 4: Comparative effectiveness data. The website does not compare Zepbound to semaglutide (Wegovy) or other GLP-1 medications. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed tirzepatide produced 20.9% mean weight loss at 15 mg versus 14.9% for semaglutide 2.4 mg in the STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021). This comparison is not on Zepbound.com. Patients who want to compare medications must consult third-party sources.

These omissions are legal and expected (Lilly is not required to advertise competitors or alternatives), but they create gaps in patient knowledge.

FormBlends clinical pattern: what patients search for after visiting Zepbound.com

Our patient intake data shows a consistent pattern: patients visit Zepbound.com first, then search for additional information when the site doesn't answer their questions. The most common post-Zepbound.com searches in our referral logs (January-March 2026):

1. "Zepbound compounded" or "tirzepatide compounding pharmacy" (41% of post-visit searches). Patients learn from the Zepbound site that the medication exists, then search for alternatives when they discover their pharmacy is backordered or their insurance won't cover it.

1. "Zepbound cost without insurance" (28%). The savings card page prompts patients to ask what they'll pay if they don't qualify for the card.

1. "Zepbound vs Wegovy" (19%). The Zepbound site does not compare to semaglutide, so patients search for head-to-head comparisons.

1. "Zepbound shortage 2026" (12%). Patients who call pharmacies and hear "we're out of stock" return to Google to understand why.

This search pattern reveals the Zepbound website's function: it's an effective awareness tool (it introduces patients to the medication), but it's not a decision-support tool (it doesn't help patients choose between options or navigate access barriers).

Patients who reach FormBlends after visiting Zepbound.com typically ask two questions the official site doesn't answer: "Can I get compounded tirzepatide instead?" and "How do I know if compounded is safe?" Our clinical intake process addresses both. (See our compounded tirzepatide safety guide for the evidence-based answer.)

When the official website is the wrong resource

The Zepbound website is the right resource if you:

• Need to watch injection technique videos for the single-dose autoinjector pen
• Want to apply for the Zepbound Savings Card (and you have commercial insurance)
• Need the full prescribing information PDF
• Want to find retail pharmacies in Lilly's distribution network

The Zepbound website is the wrong resource if you:

• Are on Medicare, Medicaid, or uninsured (the savings card does not apply to you)
• Cannot access brand-name Zepbound due to shortages or backorders (the site does not address alternatives)
• Want to compare tirzepatide to semaglutide or other GLP-1 medications (the site does not include comparative effectiveness data)
• Need guidance on compounded tirzepatide (the site does not mention compounding)
• Want real-time pharmacy inventory (the "Find a Pharmacy" tool does not show stock levels)

The decision tree for when to use Zepbound.com:

Do you already have a Zepbound prescription and brand-name supply? ├─ Yes → Zepbound.com is useful for injection videos and dose tracking └─ No → Is your barrier cost, insurance, or supply? ├─ Cost → Check if you qualify for the savings card (commercial insurance only) ├─ Insurance → Zepbound.com won't help; contact your insurer or consider compounding └─ Supply → Zepbound.com won't help; search FDA shortage database or compounding options